Analyst Called SpaceX’s Valuation: Traders Bet the Other Way
A Daiwa Securities analyst labeled SpaceX’s valuation catastrophic, while options traders bought calls, signaling a b...
Determine whether a 6-month or 12-month fund is right for you by assessing income stability, essential expenses, and personal risk appetite.
15,911 articlesA Daiwa Securities analyst labeled SpaceX’s valuation catastrophic, while options traders bought calls, signaling a b...
Coinbase posts a fee-driven growth model with a robust moat, while MicroStrategy grapples with bitcoin volatility. Th...
A political push for a different rate path could reshape markets. This article breaks down what a president donald tr...
Global regulators are tightening the rules around AI financing as investment soars, signaling potential shifts in fun...
As July nears, chatter over SpaceX joining the Nasdaq-100 swirls. This article argues that a bigger, more reliable ca...
A historic White House ceremony tied a market milestone to a child-focused investing program. Treasury confirms $1.4 ...
As SpaceX gears up for a potential IPO, spacex’s lead underwriters have produced a dramatic split in value views, cre...
Pfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
A leading mega-cap health stock dropped last year but started the year with a powerful rebound. This guide breaks dow...
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
Stellantis faces a pivotal push to revive overseas markets and lift investor confidence. This deep-dive explores the ...
America’s bone health quietly faces a looming $19 billion cost as aging Americans confront fragile bones and rising f...